 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma |
 |
 |
 |
 |
 |
 |
Keywords: |
 |
Temodar,6-Thioguanine,Celecoxib, Capecitabine,CCNU |
 |
 |
 |
 |
Phase: |
 |
Phase 2 |
 |
 |
 |
 |
 |
 |
Treatment ID#s: |
 |
VT1119
2003-0600
|
 |
 |
 |
 |
Age Group: |
 |
Adult And Pediatric |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Newly Diagnosed: N
Recurrent: Y
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Recurrent anaplastic glioma in patients at least 12 years of age |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
04/15/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Mixed Glioma Oligodendroglioma High Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent or progressive anaplastic glioma in patients who have failed previous treatments. The safety of these combination treatment will also be studied. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy. |
 |
 |
 |
 |
Contact: |
 |
MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/ |
 |
 |